Skip to Content

An efficacy and safety study of investigational drug (XP13512) compared with a concurrent placebo control in subjects with neuropathic pain associated with post-herpetic neuralgia (PHN)

Objective

This study is being done because researchers want to find out if a study drug (XP13512) is safe and whether it can help people with pain associated with post-herpetic neuralgia (PHN) by improving their physical and emotional well-being.

IRB Protocol Number
STU00003138
Principal Investigator(s)
R. Norman Harden

Clinical Trial Categories

  • Pain Research

Compensation

  • Provided
Sponsor(s)
GlaxoSmith Kline
How to Participate
  • Individuals with chronic pain as a result of post-herpetic neuralgia

 

 

Compensation Provided (You will get up to $942.80 if you finish the entire study.  If you do not finish the entire study, you will get $43.70 for each study visit completed, plus additional stipends of $126.35 at certain visits.)